中国P站

Molecular biomarkers; Early detection; Preventive oncology; Cancer screening; Liquid biopsy; Genetic markers; Proteomics; Circulating tumor DNA; Epigenetic alterations; Tumor-specific antigens; Non-invasive diagnostics; Precision medicine; Risk stratification; Prognostic indicators; Diagnostic accuracy

Introduction

The early detection of cancer is critical in improving survival outcomes and reducing the burden of advanced disease on healthcare systems. Traditional screening modalities such as imaging and tissue biopsies, while effective in certain cancers, often detect tumors at later stages or are associated with limitations in sensitivity, specificity, and invasiveness. In recent years, the field of molecular oncology has identified a promising alternative: molecular biomarkers [1-5]. These biological indicators—ranging from DNA, RNA, proteins, and metabolites to circulating tumor cells—are measurable signals of physiological and pathological processes, including carcinogenesis. Their use in early detection represents a paradigm shift in preventive oncology, offering the possibility of identifying cancerous changes at the molecular level well before clinical symptoms appear. The integration of molecular biomarkers into screening and diagnostic pathways not only enhances detection capabilities but also enables stratified risk assessment, individualized monitoring, and more precise intervention strategies. As research advances, molecular biomarkers are poised to become indispensable tools in the early and non-invasive identification of malignancies, transforming the landscape of cancer prevention and patient care [6-10].

Discussion

Molecular biomarkers are transforming the approach to early cancer detection by providing insights into tumor biology, even in its subclinical stages. Among the most well-researched biomarkers are circulating tumor DNA (ctDNA) and cell-free DNA (cfDNA), which are fragments of DNA shed by tumors into the bloodstream. These can reveal tumor-specific mutations, such as those in TP53, KRAS, or EGFR, enabling detection of genetic alterations long before tumors are visible via imaging. Liquid biopsies, which analyze such markers from blood or other body fluids, are minimally invasive, repeatable, and hold significant potential for longitudinal patient monitoring.

Protein-based biomarkers such as prostate-specific antigen (PSA) for prostate cancer and cancer antigen 125 (CA-125) for ovarian cancer have been traditionally used, though their limited specificity and false positive rates have spurred the need for more refined markers. Advances in proteomics now allow the identification of tumor-specific protein expression patterns that can serve as reliable indicators of malignancy.

In the realm of epigenetics, biomarkers such as DNA methylation patterns and histone modifications are showing promise in early detection. For example, aberrant methylation of SEPT9 in plasma DNA is used in colorectal cancer screening. These epigenetic markers often precede genetic mutations and reflect early tumor initiation, making them particularly useful for detection at a precancerous stage.

Another frontier is microRNAs (miRNAs), small non-coding RNA molecules that regulate gene expression. Specific miRNA signatures have been associated with various cancers and are detectable in blood, saliva, and urine, offering a non-invasive and accessible diagnostic modality. Similarly, long non-coding RNAs (lncRNAs) and exosomal content are gaining traction as emerging classes of biomarkers due to their role in cellular communication and tumor progression.

The utility of molecular biomarkers extends beyond detection to risk prediction, prognosis, and therapeutic monitoring. For example, individuals with BRCA1/2 mutations are at increased risk for breast and ovarian cancer and may benefit from enhanced surveillance or prophylactic interventions. Biomarker panels are also being developed to distinguish between benign and malignant lesions, thereby reducing unnecessary biopsies and patient anxiety.

The clinical implementation of these biomarkers is being accelerated by innovations in next-generation sequencing (NGS), mass spectrometry, and AI-driven data analytics, which improve detection sensitivity and allow integration of multi-omic data. Multi-cancer early detection (MCED) tests, such as those analyzing methylation signals across several tumor types, are currently in development and hold promise for broad population-level screening.

Despite their potential, several challenges must be addressed before molecular biomarkers can be widely adopted in preventive oncology. These include:

• Variability in biomarker expression: Biomarkers can be expressed by non-tumor tissues, leading to low diagnostic specificity for some, and potentially resulting in false positives and unnecessary follow-up procedures or treatments.
• Technical limitations and standardization: There is a need for robust and standardized assay validation, qualification rules (e.g., from EDRN, PACCT), and cutoff values to ensure reliable and reproducible results across different laboratories and platforms.
• Clinical validation: Large-scale, prospective clinical trials are essential to demonstrate the true clinical utility, sensitivity, and specificity of novel biomarkers in real-world settings, ensuring they genuinely improve outcomes.
• Tumor heterogeneity: Spatial and temporal heterogeneity of tumors can impact biomarker test results, making it challenging to capture the full molecular profile of a cancer.
• Cost and accessibility: Molecular diagnostics, especially advanced techniques like NGS-based liquid biopsies, can be expensive, limiting access for many individuals, particularly in low-resource settings. This can exacerbate health disparities.
• Ethical considerations: Issues like false positives can lead to patient anxiety, overdiagnosis, and potential unnecessary interventions. Additionally, the implications of identifying elevated cancer risk in otherwise healthy individuals require careful communication and supportive counseling. Privacy and data security of sensitive genetic information are also paramount.
• Reimbursement and policy: Clear reimbursement models and supportive regulatory frameworks are needed to ensure the financial sustainability and widespread adoption of these advanced diagnostic tools.

To ensure equitable benefit from these advances, policies must focus on affordability, education, and infrastructure development. Public-private collaborations, regulatory harmonization, and global data-sharing platforms can play pivotal roles in overcoming these obstacles.

Conclusion

Molecular biomarkers represent a groundbreaking advancement in the early detection and prevention of cancer. By enabling the identification of tumor-related changes at the molecular level, often before clinical manifestation, they offer a powerful supplement—or even alternative—to traditional diagnostic tools. Through non-invasive methods such as liquid biopsies and genomic profiling, clinicians can now detect, stratify, and monitor cancer risk with greater precision. While challenges related to accessibility, standardization, and clinical validation persist, ongoing research and technological progress are rapidly moving these innovations from bench to bedside. As molecular biomarkers continue to be integrated into routine preventive oncology, they hold the promise of improving early diagnosis, reducing mortality, and ushering in a new era of personalized cancer prevention.

References

1. Duarte S, Gregoire S, Singh AP, Vorsa N, Schaich K, et al. (2006). FEMS Microbiol Lett 257: 50-56.

   , ,

2. Izumitani A, Sobue S, Fujiwara T, Kawabata S, Hamada S, et al. (1993). Caries Res 27: 124-9.

   , ,

3. Gnan SO, Demello MT (1999). J Ethnopharmacol 68: 103-108.

   , ,

4. Yanagida A, Kanda T, Tanabe M, Matsudaira F, Cordeiro JGO. (2000). J Agric Food Chem 48: 5666-5671.

   , ,

5. Bhat V, Durgekar T, Lobo R, Nayak UY, Vishwanath U, et al. (2019). BMC Complement Altern Med 19: 327.

   , ,

6. Brighenti FL, Luppens SBI, Delbem ACB, Deng DM, Hoogenkamp MA, et al. (2008). Caries Res 42: 148-154.

   , ,

7. Nishimura S, Inada H, Sawa Y, Ishikawa H (2013). Eur J Cancer Care 22: 353-360.

   , ,

8. Hölttä P, Alaluusua S, Pihkala UMS, Wolf S, Nyström M, et al. (2002). Bone Marrow Transplant 29: 121-127.

   , ,

9. Proc p, Szczepa艅ska j, Skiba A, Zubowska M, Fendler W, et al.. Cancer Res Treat 48: 658-667.

   , ,

10. Voskuilen IGMVDP, Veerkamp JSJ, Raber-Durlacher JE, Bresters D, Wijk AJV, et al (2009). Support Care Cancer 17: 1169-1175.

    , ,